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ABSTRACT
We previously identified associations with ovarian cancer outcome at five genetic 
loci. To identify putatively causal genetic variants and target genes, we prioritized two 
ovarian outcome loci (1q22 and 19p12) for further study. Bioinformatic and functional 
genetic analyses indicated that MEF2D and ZNF100 are targets of candidate outcome 
variants at 1q22 and 19p12, respectively. At 19p12, the chromatin interaction of 
a putative regulatory element with the ZNF100 promoter region correlated with 
candidate outcome variants. At 1q22, putative regulatory elements enhanced MEF2D 
promoter activity and haplotypes containing candidate outcome variants modulated 
these effects. In a public dataset, MEF2D and ZNF100 expression were both associated 
with ovarian cancer progression-free or overall survival time. In an extended set of 
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INTRODUCTION
Most women diagnosed with stage III-IV ovarian 
cancer will die from the disease [1]. Although there 
has been improvement in ovarian cancer survival time, 
developments in chemotherapy have not contributed 
to a substantial decrease in deaths from ovarian cancer 
[2]. Genetic markers that identify women with poor 
prognosis or who are more likely to respond to specific 
treatment regimens could help improve outcomes by 
individualization of therapy. To this end, we recently 
performed a genome-wide association analysis of ovarian 
cancer patients treated with chemotherapy. We analyzed 
European ancestry patients based on their treatment regime 
and using a threshold of p ≤ 1×10-5 we found five variants 
that associated with either progression free survival 
(PFS) or overall survival (OS): rs4910232 (11p15.3) 
and rs3795247 (19p12), associated with PFS in patients 
who had cytoreductive surgery for first-line treatment 
regardless of chemotherapy type (referred to as the “any 
chemotherapy” group, n = 4,095); rs6674079 (1q22) 
associated with OS in the any chemotherapy group (n = 
4,426); and rs7950311 (11p15.4) and rs2549714 (16q23) 
associated with OS in patients known to have received 
first-line treatment of cytoreductive surgery and ≥4 cycles 
of paclitaxel and carboplatin intravenously at 3-weekly 
intervals (referred to as the “standard chemotherapy” 
group, n = 1,799) [3].
All five variants associated with ovarian cancer 
patient outcome, and other candidate variants correlated 
by linkage disequilibrium (r2 > 0.4), are located in non-
coding regions of the genome. The potential regulatory 
targets of these variants are not obvious, especially as 
functional elements can target genes over 1 Mb away 
through long-range chromatin interactions [4, 5]. To 
overcome this barrier and identify target genes, we used 
available bioinformatic data to prioritize two ovarian 
cancer outcome loci (1q22 and 19p12) for analysis and 
performed chromatin conformation capture and other 
functional genetic approaches to identify variants that 
regulate gene expression. We also performed further 
testing of genetic associations using additional Ovarian 
Cancer Association Consortium (OCAC) patients in a new 
meta-analysis of patient outcome.
RESULTS
ZNF100 is a potential regulatory target of 
candidate outcome variants at the 19p12 locus
The five variants associated with ovarian cancer 
patient outcome and additional candidate outcome 
variants (correlated by linkage disequilibrium, r2 > 
0.4) were assessed for effects on gene expression using 
publicly available data. In The Cancer Genome Atlas 
(TCGA) study of ovarian tumor samples (n = 386), no 
candidate outcome variants significantly associated with 
expression of genes located within 1 Mb of the lead 
variant (Bonferroni threshold p < 0.00016), although 
significant associations were observed between gene 
expression and variants that were not correlated with the 
lead outcome variants (Supplementary File 1). Analysis 
of normal ovarian samples (n = 85) from the Genotype-
Tissue Expression (GTEx) Project [6], indicated that 
minor alleles of 13 candidate variants at the 19p12 locus 
associated with increased ZNF100 expression after 
false discovery rate correction (q < 0.05, p < 1×10-5; 
Supplementary Table 1). No candidate variants at the other 
outcome loci significantly associated with gene expression 
(q < 0.05).
To determine if candidate variants at 19p12 
interact with the ZNF100 promoter region through long-
range chromatin interactions, we performed chromatin 
conformation capture (3C) analyses in COV362 and 
OVCAR8 ovarian cancer cell lines. These cell lines were 
prioritized for study based on ZNF100 expression in 
serous ovarian cancer cell lines (Supplementary Figure 1). 
Through 3C analysis across this outcome-associated locus, 
we identified two peaks of interaction, both containing 
candidate outcome variants (Figure 1). 
Putative regulatory elements (PREs) modulate 
ZNF100 promoter activity
The two chromatin interacting regions have 
the potential to regulate ZNF100 promoter activity. 
Functionality at the region most frequently interacting 
with the ZNF100 promoter was further indicated by 
the presence, in normal ovary, of H3K4me1 histone 
modification (associated with enhancers) and an enhancer 
predicted by chromatin state segmentation (Figure 1). 
6,162 epithelial ovarian cancer patients, we found that functional candidates at the 
1q22 and 19p12 loci, as well as other regional variants, were nominally associated 
with patient outcome; however, no associations reached our threshold for statistical 
significance (p<1×10-5). Larger patient numbers will be needed to convincingly 
identify any true associations at these loci.
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We defined the part of the interacting region marked by 
H3K4me1 and the predicted enhancer as ZNF100 putative 
regulatory element (PRE1) (Figure 1). We cloned ZNF100 
PRE1, containing four candidate variants into a reporter 
gene construct containing the ZNF100 promoter. A variant 
ZNF100 promoter construct containing the minor allele 
of the rs4467196 candidate variant was also generated 
but this variant did not significantly affect promoter 
activity (p > 0.05, Supplementary Figure 2) and, thus, 
we used the promoter construct carrying the common 
allele for the luciferase analysis of PREs. The reference 
ZNF100 PRE1 construct (containing the major alleles of 
the candidate variants) enhanced activity 1.25-1.43 fold 
over the construct containing the ZNF100 promoter alone 
in OVCAR8 and COV362 cells (Figure 2A-2D). Two 
candidate variants in ZNF100 PRE1 affected ZNF100 
promoter activity in OVCAR8 cells: the minor allele of 
rs10421113 increased promoter activity by 1.15 fold (p 
= 0.007; Figure 2A); and the minor allele of rs10421342 
reduced activity by 1.10 fold (p = 0.04; Figure 2A). 
However, candidate variants did not affect promoter 
activity in COV362 cells (Figure 2B), nor did haplotypes 
containing these alleles have significant effects in either 
cell line (Figure 2C-2D). 
At the second promoter-interacting region (Figure 
1), one of the candidate variants (rs4547465) associated 
with ZNF100 expression in ovarian tissue (Supplementary 
Table 1) and, thus, we cloned a region (ZNF100 PRE2; 
Figure 1) containing rs4547465 and a neighboring 
candidate variant (rs11879157) into the reporter gene 
construct containing the ZNF100 promoter. The reference 
ZNF100 PRE2 increased promoter activity 1.23 fold in 
OVCAR8 cells (Figure 2E), but had no significant effect in 
COV362 cells (Figure 2F). None of the candidate variants 
affected ZNF100 PRE2 activity in either cell line (Figure 
2E-2F).
The two potentially functional candidate variants 
in ZNF100 PRE1, rs10421113 and rs10421342, were 
Figure 1: Two regions containing candidate all chemo PFS candidate variants interact with the ZNF100 promoter in 
ovarian cancer cell lines at the 19p12 outcome locus. The figure shows 3C analyses of interactions between HindIII fragments 
and the ZNF100 promoter region (highlighted in pink) in COV362 and OVCAR8 cells. For each cell line, interaction frequencies were 
normalised to those of the fragment proximal to the promoter. Interaction frequencies from three independent biological replicates are 
shown (error bars represent standard error of the mean). The original variant associated with any chemotherapy PFS, rs3795247, is shown 
with correlated candidate outcome variants (r2 > 0.4) in black. Roadmap Consortium chromatin state segmentation for normal ovarian 
tissue using a Hidden Markov Model (Chrom HMM) is shown (red = active transcription start sites, dark green = weak transcription, 
green = strong transcription, green/yellow = genic enhancers, yellow = enhancers, aquamarine = ZNF gene repeats and turquoise = 
heterochromatin). H3K4Me1 modification in normal ovarian tissue is also indicated. Putative Regulatory Elements (PREs), and their 
coincident candidate variants, cloned into reporter gene constructs are highlighted in blue.
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amenable to allele-specific 3C analysis in OVCAR8 cells 
due to their heterozygosity and proximity to a HindIII 
restriction site used in the 3C analysis. PCR-based 
Sanger sequencing indicated that the major (G) alleles of 
rs10421113 and rs10421342 are located in a region that 
preferentially interacts with the ZNF100 promoter region 
in OVCAR8 cells (Figure 3). Notably, the minor (A) 
allele of rs10421113 weakens several binding motifs of 
CTCF (Supplementary Table 2), a transcription factor that 
is required for cell type-specific chromatin interactions 
[7]. Allele-specific 3C analysis of ZNF100 PRE1 could 
not be performed in COV362 cells as this cell line was 
not heterozygous for rs10421113 and rs10421342. Allele-
specific 3C analysis also could not be performed for 
ZNF100 PRE2 as an amenable heterozygous candidate 
variant was not found in either OVCAR8 or COV362 
cells.
Candidate variants in an ovarian super-enhancer 
at 1q22 modify MEF2D promoter activity
Super-enhancers are dense clusters of enhancers 
and have been found to be enriched for disease associated 
variants in previous studies [8, 9]. We interrogated a 
catalogue of super-enhancers across 86 human cell and 
tissue types [9] and found candidate variants at the 1q22 
outcome locus were coincident with super-enhancers 
present in multiple tissues (Supplementary Table 3), 
Figure 2: ZNF100 PRE1 and PRE2 enhance promoter activity in OVCAR8 cells. ZNF100 PRE1 and PRE2 regions containing 
the major alleles of candidate outcome variants were cloned downstream of a ZNF100-promoter-driven luciferase construct (ZNF100 
promoter in figure) for the creation of reference (PRE1 ref and PRE2 ref) constructs. Minor allelic variants of the outcome variants 
were engineered into constructs and are designated by the rs ID of the corresponding variant and a black box in the construct schematic. 
Constructs containing haplotypic variants occurring in Europeans were also generated: PRE1 hap2 (minor allelic variants of all candidate 
variants except for rs4808295; 10% frequency in Europeans) and PRE1 hap3 (all minor allelic variants; 4% frequency in Europeans); and 
PRE2 hap2 (all minor allelic variants). Cells were transiently transfected with each of these constructs and assayed for luciferase activity 
after 24 h. Back-transformed data are shown and error bars denote 95% confidence intervals of experiments performed in triplicate for 
OVCAR8 cells and in quadruplicate for COV362 cells. P-values were determined by two-way ANOVA followed by Dunnett’s multiple 
comparisons test (*p  < 0.05, **p < 0.01 and ***p < 0.001).
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including normal ovary (Figure 4). A region containing 
four candidate outcome variants and substantial levels of 
H3K4Me1 in normal ovary was defined as MEF2D PRE1 
(Figure 4). Three of these candidate outcome variants were 
also coincident with the ovarian super-enhancer which was 
predicted by the catalogue to regulate MEF2D through 
pairing of the super-enhancer with the nearest expressed 
gene in normal ovary [9]. Queries of GTEx eQTL data, 
indicated that the minor allele of one of MEF2D PRE1 
candidate variants, rs11264489, was nominally associated 
(p = 0.032) with lower MEF2D expression in ovarian 
tissue (Supplementary Table 4). The three MEF2D PRE1 
candidate variants in the ovarian super-enhancer were also 
located within RP11-284F21.8, a long non-coding RNA 
(lncRNA). Notably, lncRNAs are often associated with 
enhancer regions [10]. 
A multi-tissue super-enhancer region containing 
candidate outcome variants was observed near the 3’ 
end of IQGAP3 at 1q22 (Figure 4). In particular, two 
candidate outcome variants adjacent to the 3’ end of 
IQGAP3, rs947661 and rs7550381, coincided with super-
enhancers from 17 tissues, 16 of which were predicted to 
target MEF2D (Supplementary Table 3). This region was 
defined as PRE2. To further explore the potential target of 
these two variants, GTEx eQTL data for normal ovarian 
tissue were queried and nominally significant (p≤0.015; 
Supplementary Table 4) associations were observed 
between lower MEF2D expression and the minor alleles of 
both variants, but not with expression of the neighboring 
IQGAP3 gene.
The MEF2D promoter was too close to the 
candidate outcome variants for analysis of DNA chromatin 
interactions by 3C but the super-enhancer and GTEx eQTL 
data suggested that MEF2D is a regulatory target. To 
examine the effects of variants on activity of the MEF2D 
promoter, we tested the effects of the four candidate 
outcome variants in MEF2D PRE1 on promoter activity 
in OVCAR8 and JAM cells, the two ovarian cancer 
cell lines in which MEF2D was most highly expressed 
(Supplementary Figure 1). The reference MEF2D PRE1 
construct, containing the most common European 
haplotype (1000 Genomes Project) of the four candidate 
variants, acted as an enhancer of promoter activity. 
Compared with a reporter gene construct containing the 
Table 1: Meta-analysis of 1q22 and 19p12 loci for genetic association with survival outcomes in ovarian cancer patients
Variant Position (hg19)
OS any chemotherapy 
(n=6,160)
OS standard chemotherapy 
(n=2,620)
PFS any chemotherapy 
(n=5,596)
PFS standard 
chemotherapy (n=2,352)
Effect 
allele/
Ref 
allele
EAF§ HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
1q22 region
rs6674079* 156486061 A/G 0.60 0.93 (0.88-0.98) 0.010 0.95 (0.88-1.04) 0.257 0.98 (0.93-1.03) 0.398 1.00 (0.93-1.08) 0.918
rs11264494¶ 156493398 C/T 0.51 0.91 (0.86-0.96) 2.6×10-4 0.91 (0.84-0.99) 0.023 0.92 (0.88-0.97) 0.001 0.92 (0.86-0.99) 0.024
rs2274500¶ 156850112 G/T 0.86 1.09 (0.98-1.21) 0.110 1.24 (1.06-1.45) 0.007 1.05 (0.95-1.16) 0.312 1.16 (1.00-1.35) 0.047
rs60989774¶ 156513579 CT/C 0.38 1.08 (1.02-1.14) 0.006 1.08 (1.00-1.18) 0.061 1.11 (1.05-1.17) 8.0×10-4 1.11 (1.02-1.20) 0.011
rs59359496¶ 156501450 T/G 0.08 1.04 (0.95-1.14) 0.422 1.07 (0.93-1.23) 0.340 1.13 (1.03-1.23) 0.007 1.21 (1.07-1.38) 0.003
rs947661# 156494916 A/G 0.36 1.10 (1.04-1.16) 8.2×10-4 1.09 (1.00-1.19) 0.050 1.04 (0.99-1.10) 0.118 1.04 (0.96-1.12) 0.367
rs10159180# 156480324 C/T 0.46 0.92 (0.87-0.97) 0.001 0.93 (0.86-1.01) 0.089 0.94 (0.89-0.98) 0.007 0.95 (0.88-1.02) 0.176
rs942964# 156481707 A/G 0.54 1.09 (1.03-1.15) 0.001 1.07 (0.99-1.16) 0.097 1.07 (1.02-1.12) 0.010 1.05 (0.98-1.13) 0.178
rs11264488# 156480288 C/G 0.56 1.08 (1.03-1.14) 0.004 1.05 (0.97-1.14) 0.194 1.07 (1.02-1.13) 0.005 1.05 (0.98-1.13) 0.171
rs11264489# 156480831 A/G 0.60 0.92 (0.87-0.97) 0.004 0.95 (0.87-1.03) 0.194 0.98 (0.93-1.03) 0.365 1.00 (0.93-1.08) 0.990
rs7550381# 156495001 A/G 0.60 0.92 (0.87-0.97) 0.004 0.94 (0.87-1.03) 0.181 0.96 (0.92-1.01) 0.156 0.98 (0.91-1.06) 0.604
19p12 region
rs3795247* 21906428 T/C 0.90 0.90 (0.82-0.98) 0.021 0.80 (0.69-0.93) 0.003 0.89 (0.82-0.97) 0.007 0.83 (0.73-0.95) 0.009
rs79447188¶ 22405414 T/C 0.03 1.20-(1.05-1.37) 0.006 1.26 (1.03-1.55) 0.024 1.13 (1.00-1.28) 0.044 1.10 (0.90-1.34) 0.342
rs4330044¶ 21905838 T/C 0.10 1.12 (1.02-1.22) 0.021 1.25 (1.08-1.44) 0.003 1.13 (1.03-1.23) 0.007 1.20 (1.05-1.38) 0.009
rs35308521¶ 21932095 G/GA 0.11 1.12 (1.02-1.23) 0.015 1.24 (1.08-1.43) 0.003 1.14 (1.05-1.25) 0.002 1.21 (1.06-1.38) 0.005
rs12463030¶ 21947607 T/C 0.95 0.88 (0.76-1.01) 0.071 0.76 (0.60-0.95) 0.016 0.85 (0.74-0.97) 0.015 0.72 (0.58-0.89) 0.002
rs10421113# 21929885 T/C 0.83 1.02 (0.95-1.10) 0.575 1.11 (0.99-1.24) 0.065 1.04 (0.98-1.11) 0.227 1.11 (1.00-1.23) 0.047
rs10421342# 21930003 T/C 0.83 1.02 (0.95-1.10) 0.575 1.11 (0.99-1.24) 0.065 1.04 (0.98-1.11) 0.227 1.11 (1.00-1.23) 0.047
§Effect allele frequency based on samples from the OncoArray study.
*Lead outcome variant in our original study [3].
¶Lead outcome variant with a survival phenotype in the new meta-analysis.
#Functional candidate variant.
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MEF2D promoter alone, the reference MEF2D PRE1 
increased MEF2D promoter activity by 2.2-2.9 fold in 
OVCAR8 and JAM cells (Figure 5A-5B). In OVCAR8 
cells, candidate variants did not individually show an 
effect but a haplotype (MEF2D PRE1 hap2) containing the 
alternate alleles of the variants in the reference construct 
had 1.21 fold (p = 0.03) greater activity than the reference 
MEF2D PRE1 (Figure 5A). It appears that the alternate (C) 
allele of rs11264488 is necessary for the haplotype effect 
as MEF2D PRE1 hap3, which does not contain this allele, 
has no effect on the PRE activity. Furthermore, this allele 
weakens the binding motif of FOXP1 (Supplementary 
Table 2), a transcriptional repressor [11] that appears to act 
as an oncogene in ovarian cancer [12]. In JAM cells, none 
of the candidate variants, or their haplotypes, affected 
MEF2D promoter activity (Figure 5B). MEF2D PRE2 
also acted as an enhancer and increased MEF2D promoter 
activity 2.5-2.8 fold in OVCAR8 and JAM cells (Figure 
5C-5D). The MEF2D PRE2 candidate variants, rs7550381 
and rs947661, had no effect in OVCAR8 cells (Figure 
5C), but in JAM cells their minor alleles were associated 
with 17% (p = 0.03) and 19% (p = 0.01), greater MEF2D 
PRE2 activity, respectively (Figure 5D). Notably, the 
minor allele (A) of rs7550381 strengthened two binding 
motifs of CTCF (Supplementary Table 2). The effect of 
these alleles appeared to be additive as the haplotype 
containing both (MEF2D PRE2 hap2) had 38% (p = 
0.0002) greater activity (Figure 5D). We also cloned the 
Figure 3: Allele-specific interaction between ZNF100 PRE1 and ZNF100 promoter region. OVCAR8 cells are heterozygous 
for rs10421113 and rs10421342 candidate outcome variants. Allele-specific 3C analysis using PCR-based Sanger sequencing of two 
independent 3C libraries indicates that sequence containing the major G allele of both variants preferentially interacts with the ZNF100 
promoter.
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promoter of the RP11-284F21.8 lncRNA into the MEF2D 
PRE1 and MEF2D PRE2 constructs to assess its effects 
but measurable levels of RP11-284F21.8 promoter activity 
were not detected (data not shown).
MEF2D and ZNF100 expression is associated with 
poorer ovarian cancer outcome
The Kaplan-Meier plotter (KM-plot) web-based 
application [13] was used to assess associations between 
MEF2D and ZNF100 expression and outcome using data 
available from serous ovarian cancer patients. For MEF2D, 
no significant associations with OS were observed using 
data from three different probe sets (n = 453-1138; 
Supplementary Figure 3), but higher expression associated 
(p<0.05) with shorter PFS and the associations observed 
from the two probe sets with the largest number of samples 
(n = 1019) also passed a false discovery rate correction (q 
< 0.05) (Supplementary Figure 4). For ZNF100, higher 
expression was significantly associated with shorter OS 
(p = 0.013, q = 0.035; n = 453) but no association was 
observed with PFS (n = 397) (Supplementary Figure 5). 
Analysis of 1q22 and 19p12 outcome loci using a 
denser genotyping platform and additional patients
To refine the genetic associations at the 1q22 
and 19p12 outcome loci, we analyzed 1 Mb regions 
encompassing both lead variants using a denser genotyping 
platform (OncoArray [14]) than had been previously 
applied to the OCAC patient set [3]. Additionally, to 
perform analyses in the largest possible number of 
patients, we meta-analyzed data in an expanded patient set 
that included patients from our previous study [3]. After 
quality control and data cleaning, the following numbers 
of patients were included in meta-analysis: for OS, 6,160 
with any chemotherapy (N = 4,426 previously [3]), 
2,620 with standard chemotherapy (N = 1,799 previously 
[3]); for PFS, 5,596 with any chemotherapy (N = 4,095 
previously [3]) and 2,352 with standard chemotherapy (N 
= 1,958 previously [3]). However, none of the associations 
tested reached our previous threshold for significance (p < 
1.0×10-5 [3]) in any analysis (Table 1).
At 1q22, the previous lead variant, rs6674079, was 
only nominally significant for association with OS among 
patients with any chemotherapy: p = 0.01 (Table 1) versus 
p = 7.1x10-6 previously; the strongest nominal association 
at this locus for this group was with rs11264494 (p = 
Figure 4: Candidate outcome variants at 1q22 are coincident with an ovarian super-enhancer that is predicted to 
target MEF2D. The figure shows candidate outcome variants, H3K4Me1 modification in normal ovarian tissue and super-enhancers 
(ovarian super-enhancer is colored green and super-enhancers from other tissues blue) at the 1q22 ovarian outcome locus that are predicted 
to target MEF2D (Supplementary Table 3). Putative Regulatory Elements (PREs), and their coincident candidate variants, cloned into 
reporter gene constructs are highlighted in blue. The original lead variant associated with any chemotherapy OS, rs6674079, is shown with 
correlated candidate outcome variants (r2 > 0.4) in black and the lead variant from the new OncoArray analysis with all chemotherapy OS, 
rs11264494, in blue (region cloned into reporter gene constructs highlighted in purple). 
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2.6x10-4, Table 1). Of the candidate variants in haplotypes 
with functional effects on MEF2D promoter activity, the 
strongest association was observed between PRE2 variant 
rs947661 and any chemotherapy OS (p = 8.2x10-4; Table 
1). Other candidate variants from functional haplotypes 
also nominally associated with OS and PFS among 
patients treated with any chemotherapy, but no variant 
at 1q22 passed our significance threshold of p < 1x10-5 
(Table 1). Linkage disequilibrium was observed between 
the previous lead candidate, rs6674079, and rs11264494 
(r2 = 0.33 in Europeans) and also between rs11264494 and 
candidate variants from the haplotypes with functional 
effects on MEF2D promoter activity (r2 = 0.33-0.79).
At 19p12, the association of the previous lead 
variant, rs3795247, with any chemotherapy PFS also lost 
significance: p = 0.007 versus p = 1.05x10-5 previously 
(Table 1). The strongest nominal association at this 
locus was between rs35308521 and any chemotherapy 
Figure 5: MEF2D regulatory regions act as enhancers and candidate outcome variants increase MEF2D PRE1 and 
PRE2 activity. Putative MEF2D regulatory regions containing candidate outcome variants were cloned downstream of a MEF2D-
promoter-driven luciferase construct (MEF2D promoter in figure). The reference PRE1, PRE2 and rs11264494 constructs contain the most 
common haplotypes or alleles in Europeans. Alternative alleles of candidate outcome variants were engineered into constructs and are 
designated by the rs ID of the corresponding variant and a black box in the construct schematic. Constructs containing other haplotypes 
were also generated: PRE1 hap2 (all alternative alleles of PRE1 ref; 35% frequency in Europeans) and hap3 (all alternative alleles of PRE1 
ref except rs11264488; 15% frequency in Europeans); and PRE2 hap2 (all alternative alleles of PRE2 ref; 30% frequency in Europeans). 
Cells were transiently transfected with each of these constructs and assayed for luciferase activity after 24 h. Back-transformed data are 
shown and error bars denote 95% confidence intervals of replicate experiments performed in OVCAR8 and JAM cells. P-values were 
determined by two-way ANOVA followed by Dunnett’s multiple comparisons test (*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 
0.0001).
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PFS (p = 0.002, Table 1). For the two candidate variants 
that correlated with the allele-specific chromatin 
interaction with the ZNF100 promoter region, nominal 
associations with outcome were observed only in the 
standard chemotherapy PFS analysis (Table 1). Linkage 
disequilibrium was observed between the previous lead 
candidate, rs3795247, and rs35308521 (r2 = 0.89) and 
between rs35308521 and the two variants that correlated 
with allele-specific looping with the ZNF100 promoter 
region (r2 = 0.47).
rs11264494 does not affect MEF2D promoter 
activity
Based on the results from the new genetic analysis, 
the variant with the strongest nominal association with 
outcome at either locus was rs11264494, located near the 
MEF2D PRE2 and proximal to several MEF2D super-
enhancers (Figure 4). A region containing this variant was 
cloned in the luciferase reporter construct containing the 
MEF2D promoter. The region containing the (C) allele 
of rs11264494 enhanced MEF2D promoter activity 2.4-
fold in OVCAR8 and 3.6-fold in JAM cells, but the T 
allelic variant of this SNP did not significantly affect this 
enhancer activity (Figure 5E-5F).
DISCUSSION
We have performed follow-up analyses of the 
1q22 and 19p12 ovarian cancer outcome loci to identify 
functional genetic variants and refine the genetic 
associations. At the 1q22 locus, candidate outcome 
variants were located in an ovarian super-enhancer and 
haplotypes containing these variants had differential 
effects on MEF2D promoter activity. At the 19p12 locus, 
an allele-specific chromatin interaction with the ZNF100 
promoter region was observed with two candidate 
outcome variants. Candidate functional variants at both 
loci nominally associated with survival outcome; however, 
neither these, nor other variants at either locus, passed our 
significance threshold (p < 1×10-5).
MEF2D encodes the myocyte enhancer factor 2D, a 
transcription factor that was initially found to be associated 
with muscle cell differentiation [15] but which also affects 
tumor development and progression [16]. Notably, in 
patients diagnosed with osteosarcoma, hepatocellular 
carcinoma or colorectal cancer, poorer prognosis is 
associated with greater MEF2D expression [16-18]. Using 
publicly available data, we also identified associations 
between greater MEF2D expression and shorter PFS in 
women with serous ovarian cancer. Consistent with these 
observations, the C allele of rs11264488, the functional 
variant most strongly associated with any chemotherapy 
PFS, appears to be a requisite component of the MEF2D 
PRE1 haplotype with the greatest enhancer effect on 
MEF2D promoter activity. However, as this variant was 
only nominally associated with any chemotherapy PFS, 
links between its molecular effect and a clinical phenotype 
remain speculative.
ZNF100 encodes a zinc finger protein transcription 
factor of which little is known, although the literature 
indicates that this gene may have a role in cancer. ZNF100 
is among the 30 most hypermethylated genes in colorectal 
cancer [19] and is frequently mutated in multiple myeloma 
with mutated alleles preferentially expressed [20]. 
Knockdown screens have shown that ZNF100 knockdown 
sensitizes gastrointestinal stromal tumor cells to sunitinib 
and imatinib treatment [21]. The 19p12-13 region is 
amplified in ovarian cancer and ZNF100, and other ZNF 
genes, show increased expression in tumors with these 
amplifications [22]. In a public dataset, we identified 
an association between greater ZNF100 expression 
and shorter OS but we have not been able to find direct 
evidence that candidate outcome variants at 19p12 up-
regulate ZNF100 expression.
This study has several limitations which should 
be noted. The clinical analysis is based on observational 
data and a lack of treatment standardization in our any 
chemotherapy analyses may cloud genetic associations; 
however, we had hypothesized that the analysis of a 
more homogenous treatment group in our standard 
chemotherapy analyses could reveal variants with greater 
effects, thus increasing power to detect associations. 
Nevertheless, it has become apparent that very large 
numbers of samples are needed to detect patient outcomes 
that are associated with common genetic variation. In the 
context of this study, 11,001 survival events are needed to 
detect with 80% power at p < 1×10-5 a variant with a minor 
allele frequency of 0.4 that confers a HR of 1.1. Therefore, 
though we cannot rule out associations between genetic 
variation at 1q22 and 19p12 with ovarian cancer patient 
outcome, larger patient numbers will be needed to identify 
true associations.
MATERIALS AND METHODS
TCGA eQTL analyses in ovarian cancer samples
Data from ovarian cancer patients were accessed 
from The Cancer Genome Atlas (TCGA; https://tcga-
data.nci.nih.gov/). Tumor gene expression microarray data 
(Agilent G4502A platform) and copy-number information 
were downloaded through the public access TCGA 
portal. Germline genotypes (Affymetrix 6.0 arrays) were 
downloaded through the TCGA controlled access portal 
and QC performed. Variants were excluded for call rate 
< 95%, MAF < 1% or deviations from HWE significant 
at 10-4. Thirteen samples were excluded for low overall 
call rate ( < 95%), heterozygosity > 3 standard deviations 
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from the mean or non-female sex status (X-chromosome 
homozygosity > 0.2). A pair of samples were identified as 
duplicates by identity-by-state probabilities = 0.99) and 
the sample with the lower call rate was excluded. Overall 
there were 386 TCGA patients with complete genotype, 
gene expression and copy-number data included in the 
analysis. Gene expression for genes 500kb upstream 
and downstream of each locus were adjusted for somatic 
copy number variation, as previously described [23]. The 
associations between genotype and adjusted expression for 
each gene were evaluated using linear regression models 
by PLINK [24].
Cell lines
ES-2, COV318, COV362 cells were cultured in 
Dulbecco’s Modified Eagle Medium and non-essential 
amino acids; FUOV1 cells were cultured in DMEM/F12 
with L-Glutamine; and JAM and OVCAR8 cells were 
cultured in RPMI1640 with L-glutamine. All cell lines 
were cultured with 10% fetal calf serum and penicillin/
streptomycin at 37°C in a humidified 5% CO2 atmosphere. 
Cell lines were stored in liquid nitrogen vapor phase with 
Mycoplasma testing and short tandem repeat profiling 
performed for cell line authentication prior to storage.
Real-time PCR (qPCR)
RNA was extracted from cells using Trizol 
(Life Technologies) and cDNA synthesised using 
the SuperScript III First-Strand Synthesis System 
(Life Technologies) according to the manufacturer’s 
instructions. mRNA expression was quantified by real-
time PCR reactions using Syto9 and qPCR primers 
(Supplementary Table 5) with normalisation by ACTB 
expression.
Chromatin conformation capture (3C)
3C libraries were generated from OVCAR8 and 
COV362 cells using HindIII (New England Biolabs) 
as described previously [25]. 3C interactions were 
quantified by qPCR with primers designed within the 
HindIII restriction fragments spanning the 19p12 outcome 
locus (Supplementary Table 5). qPCR was performed 
as described previously [26] using three independent 
3C libraries from each cell line with each experiment 
quantified in duplicate. Two BAC clones (RP11-120C22 
and RP11-420K14: BACPAC Resource Center) covering 
the 19p12 outcome locus were used to create an artificial 
library of ligation products in order to normalize for PCR 
efficiency. As an internal control, interaction frequencies 
were normalized to that of the HindIII fragment 
immediately upstream of the promoter/bait fragment. 
To perform allele-specific 3C, DNA was amplified by 
PCR of two independent 3C libraries using the bait and 
a reverse primer specific to a PRE1 fragment containing 
rs10421113 and rs10421342 (Supplementary Table 5). 
Sanger sequencing (Australian Genome Research Facility, 
Brisbane) was performed to determine the alleles present 
in the interacting PRE1 fragment.
Reporter gene vector construction
MEF2D and ZNF100 promoter-driven luciferase 
reporter constructs were generated by inserting 2119 
and 703 bp of DNA PCR-amplified from the respective 
promoters into the KpnI and HindIII sites of pGL3-Basic. 
To assist cloning of PREs downstream of the Firefly 
luciferase gene in pGL3-Basic, additional restriction sites 
had been introduced in a modified pGL3-Basic construct 
[27] and AgeI and SalI were then used to insert PREs into 
pGL3-Basic. For ZNF100 PRE1 and PRE2, a 1010 bp 
fragment was PCR generated using primers engineered 
with AgeI and SbfI sites and a 463 bp fragment (hg19, 
chr19:21900737-21901199) synthesized with terminal 
AgeI and SbfI sites (Integrated DNA Technologies, 
Singapore) for cloning into a modified pGL3-ZNF100 
promoter construct, respectively. For MEF2D PRE1 and 
PRE2, a 1917 bp fragment and a 1723 bp fragment were 
also PCR generated as above and cloned into a modified 
pGL3-MEF2D promoter construct, respectively. The 
477 bp rs11264494 construct (hg19, chr1:154693242-
156493718) was also synthesized by Integrated DNA 
Technologies and cloned as above. The minor alleles of 
individual variants were introduced into cloned sequences, 
containing the major alleles of any other causal candidate 
variants, by overlap extension PCR. Common haplotypes 
predicted to be present in Europeans, from analyses of 
1,000 Genomes Project data accessed via the LDlink web-
based application [28], were also generated. All constructs 
were sequenced to confirm variant incorporation (AGRF, 
Brisbane, Australia). PCR cloning and sequencing primers 
are listed in Supplementary Table 5. 
Reporter assays
COV362 and OVCAR8 cells were transfected 
with equimolar amounts of luciferase reporter plasmids 
and 50 ng of pRLTK transfection control plasmid with 
Lipofectamine 2000 (Life Technologies). The total 
amount of transfected DNA was kept constant at 600 ng 
for each construct by adding pUC19 as a carrier plasmid. 
Luciferase activity was measured 24 h post-transfection 
by the Dual-Glo Luciferase Assay System (Promega). 
To correct for differences in transfection efficiency or 
cell lysate preparation, Firefly luciferase activity was 
normalized to Renilla luciferase. All promoter constructs 
had greater activity than the empty pGL3-Basic construct 
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which was used as a negative control. Data were log-
transformed and statistical significance was tested by two-
way ANOVA followed by Dunnett’s multiple comparisons 
test in GraphPad Prism.
Patient samples and genotyping
Genotype analyses were restricted to invasive 
epithelial ovarian cancer patients of European ancestry 
with detailed chemotherapy and clinical follow-up for 
disease progression and survival following first-line 
treatment from OCAC and TCGA (Supplementary Table 
6). PFS was defined as the interval between the date 
of histological diagnosis and the first confirmed sign 
of disease progression or death; OS was the interval 
between the date of histological diagnosis and death from 
any cause. Criteria for progression for OCAC patients 
have been previously described [29]. TCGA genotype 
data were downloaded through the TCGA data portal 
and assessed for ancestral outliers to determine those 
of European descent. Genotype data for analysis of 
variants at the 19p12 and 1q22 loci were available from 
OCAC, with samples being genotyped with the Illumina 
Infinium OncoArray-500K beadchip. Duplicate pairs of 
samples and first degree relative pairs were identified 
and the sample with the lower call rate was removed as 
appropriate. Genotype, detailed clinical follow-up and 
pathology data were available for 5,508 EOC patients from 
24 OCAC sites. Meta-analyzed data included OncoArray 
dataset described above, the iCOGS (n = 317) samples 
which were independent to the OncoArray genotyped 
patient set) and TCGA datasets (n = 337) [3, 30]. In each 
case imputation was carried out using SHAPEIT and 
IMPUTE2 [31] and the 1000 Genomes phase 3 reference 
dataset, NCBI build b37, (October 2014 release). All 
studies received approval from their respective human 
research ethics committees, and all OCAC participants 
provided written informed consent. 
Statistical analysis
The associations between genotypes and PFS 
and OS were assessed for patients in the standard 
chemotherapy subset and the less restrictive any 
chemotherapy group. Patients who had an interval of > 
12 months between the date of histological diagnosis 
and DNA collection were excluded from the analysis to 
avoid survival bias. Cox regression models adjusted for 
residual disease (nil vs. any), tumor stage (FIGO stage 
I-IV), histology (serous, mucinous, endometrioid, clear 
cell, other epithelial), tumor grade (low vs. high), age at 
diagnosis (OS only), nine European ancestry principal 
components, and stratified by study, were used to obtain 
the per-allele hazard ratio HR and standard error for each 
variant. We tested the proportional hazards assumption for 
the adjusted variables and stratified by those that violated 
the assumption, as described previously [30]. The effect 
estimates in the largest available dataset using data from 
different genotyping platforms were derived from fixed 
effects meta-analysis of platform-specific estimates. 
We evaluated associations with OS and PFS for each 
variant (minor allele frequency > 0.02, imputation quality 
INFO score > 0.9) within a 1 Mb region encompassing 
the original lead variants at the 19p12 and 1q22 loci. All 
tests for association were two-tailed and performed using 
STATA SE v. 13 (Stata Corp., USA) and the R project for 
Statistical Computing version 3.2.2 (http://www.r-project.
org/). 
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